BALAXI PHARMACEUTICALS LIMITED — PPTs, 13-02-2025: Investor Presentation

**Financial Highlights:** In Q3 FY25, Balaxi Pharmaceuticals reported revenue of INR 73.29 crore, up 20.58% year-over-year. Gross profit dipped to INR 29.45 crore, translating to a gross margin of 40.19%, a decline of 987 bps. EBITDA before exceptional items fell 41.39% to INR 7.93 crore, with a margin of 10.81%. Profit after tax was INR 5.36 crore, showing a 55.15% decrease.

**Strategic Initiatives and Growth Drivers:** The company secured 17 new product registrations, bringing its total to 897 across seven countries. The upcoming pharmaceutical manufacturing facility in Hyderabad is set for completion by April 2025 and will significantly enhance supply chain integration.

**Business Developments:** Balaxi aims to expand its reach into new Latin American markets, with ongoing operations in Honduras and El Salvador showing positive results despite challenges in other regions.

**Market Position and Competitive Advantage:** The company's asset-right strategy aims to establish a strong foothold in key geographies, leveraging its existing distribution network while adapting to local demand dynamics for greater market penetration.

**Investor Implications:** The positive momentum in new market entries and strategic investments in manufacturing facilities indicate strong future growth potential, making Balaxi a stock to watch closely for retail investors.